Can You Take Mounjaro With Sertraline?

Why 'no known interaction' still needs context

Sertraline is an SSRI, it raises serotonin availability in the brain and has no direct effect on the gut hormone receptors that tirzepatide targets. The pathways do not cross in a way that makes one medicine undermine the other. What does matter is something more mechanical: Mounjaro slows the rate at which your stomach empties its contents into the small intestine, and that slowdown can shift the absorption curve of any oral medicine you take alongside it.

For most medicines this shift is modest and clinically insignificant. Sertraline is absorbed across the gastrointestinal tract over a broad time window, so a delay in gastric emptying is unlikely to affect how much of the drug reaches your system overall. The NHS medicines page for tirzepatide advises telling your doctor about all medicines you take, including those bought without a prescription, precisely because this kind of nuance is prescriber territory. It is not a reason to avoid the combination; it is a reason to have the conversation.

If you take sertraline at a fixed time each day, continuing that routine is sensible. Drastic timing changes to established antidepressant regimens are rarely advised without clinical input. Your prescriber is the right person to say whether anything about your particular dose or schedule warrants adjustment.

The side-effect picture when both medicines are on board

This is the practical consideration that catches people off guard. Mounjaro's most common early side effects are gastrointestinal: nausea, loose stools, indigestion and, for some people, a general feeling of fatigue in the first week or two of a new dose. Sertraline has a similar early profile, nausea, upset stomach and tiredness are common in the first couple of weeks of starting or increasing the dose.

If you begin Mounjaro while already established on sertraline, the sertraline-related GI effects will likely have settled long ago. What you notice when tirzepatide starts will almost certainly be tirzepatide. If, however, you are new to both around the same time, teasing apart which medicine is responsible for a queasy morning becomes genuinely difficult. That ambiguity matters because the management strategies differ: Mounjaro nausea often responds to eating smaller, plainer meals and staying hydrated, while new-antidepressant nausea tends to pass on its own within days.

You can read more about fatigue during Mounjaro treatment and why it happens, it is one of the questions our prescribers hear most often in the early weeks.

The decision: should you mention sertraline in your consultation?

Yes, always. This is not a formality. The clinical review at nume (carried out by a GPhC-registered Independent Prescriber who reads your answers personally) asks about your current medications for exactly this reason. A prescriber cannot make a fully informed recommendation without that picture, regardless of whether a formal interaction exists in the reference literature.

Disclosing sertraline lets the prescriber do several useful things: note the gastric-emptying consideration, flag any overlap in side effects to watch for, and check whether your sertraline dose or any associated conditions (such as a history of low mood or eating patterns linked to mental health) affect the overall suitability assessment. The BNF tirzepatide entry is the reference your prescriber works from; it covers interactions and special considerations in clinical detail.

If you are thinking about the cost side of starting Mounjaro, the Mounjaro pricing page sets out what private treatment involves and what is included. Once you are ready, checking your eligibility takes a few minutes and starts the clinical review process.

Other medicines that deserve the same conversation

Sertraline is one example of a broader principle. Anyone taking oral hormonal contraceptives alongside Mounjaro should know that tirzepatide's effect on gastric emptying can reduce pill absorption, UK guidance recommends adding a non-oral method for the first four weeks of treatment and for four weeks after each dose increase. This does not apply in the same way to semaglutide (Wegovy), which is worth knowing if you are comparing options; the dedicated page on Mounjaro and HRT covers the parallel question for hormone replacement therapy.

More generally, anyone curious about which medicines interact with GLP-1 receptor agonists will find the GLP-1 combinations page useful. And if sertraline is the main thing on your mind right now, the detailed clinical discussion is covered on the Mounjaro and sertraline page. The short answer remains the same: no contraindication, disclose everything, let a prescriber confirm suitability for you specifically.